Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Vertex Pharmaceuticals Inc. said its third quarter loss widened amid increased costs and hiring stemming from the anticipated launch of its drug target for hepatitis C next year.
“We remain focused on the completion of the telaprevir Phase 3 registration program and are on track to submit a telaprevir New Drug Application in the second half of 2010,” said Vertex chairman and CEO Matthew Emmens in a prepared statement.
The Cambridge-based biotechnology firm posted a loss of $149.6 million in the third quarter, compared with a $130 million loss for the corresponding period in 2008.
The company’s revenue declined to $25 million for the three months ended Sept. 30, down from $31.6 million during the third quarter of 2009.
Vertex had $856.6 million in cash on hand as of Sept. 30.
At the beginning of October, Vertex came out with news that it will receive an expected total cash infusion of $155 million stemming from two separate milestone-related transactions.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
